Serum Level of Vitamin D in Patients with Salivary Gland Tumors

Document Type : Original


1 Department of Orthodontics, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.

2 Otolaryngology Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

3 Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

4 Oral and Dental Disease Research Center, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.

5 Department of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.



The active vitamin D metabolites have anticancer effects on many human neoplasms. The vitamin D receptors have been detected in salivary glands tissue. This study aimed to evaluate the serum level of vitamin D in patients with malignant and benign salivary gland tumors.

Materials and Methods:

In this retrospective and cross-sectional study, 151 participants, including 42 patients with benign, 42 malignant salivary gland tumors, and 67 healthy subjects, participated. The serum level of vitamin D was measured using an enzyme-linked immunosorbent assay (ELISA).


The mean serum level of vitamin D was 42.7 ng/mL in patients with benign tumors, 40 ng/mL in malignant tumors, and 36.7 ng/mL in the control group. There was no significant difference between the mean vitamin D level and vitamin D status in patients with salivary gland tumors and normal controls (P=0.2). There was a significant positive correlation between vitamin D level and age in the control group (P=0.04).


The results showed a high prevalence rate of vitamin D deficiency/insufficiency in salivary gland tumors and normal subjects, with no significant difference. Therefore, the serum level of vitamin D might not play a significant role in the pathogenesis of these tumors, similar to many human cancers. However, further prospective studies are recommended focusing on specific tumors and considering other interventional factors.


Main Subjects

  1. Araya J, Martinez R, Niklander S, Marshall M, Esguep A. Incidence and prevalence of salivary gland tumours in Valparaiso, Chile. Med Oral Patol Oral Cir Bucal 2015;20:e532-9.
  2. Radoi L, Barul C, Menvielle G, Carton M, Matrat M, Sanchez M, et al. Risk factors for salivary gland cancers in France: Results from a case-control study, the ICARE study. Oral Oncol 2018;80:56-63.
  3. Mozaffari HR, Ramezani M, Janbakhsh A, Sadeghi M. Malignant Salivary Gland Tumors and Epstein-Barr Virus (EBV) Infection: A Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev 2017;18:1201-6.
  4. de Siqueira EC, de Souza FTA, Gomez RS, Gomes CC, de Souza RP. Does cell phone use increase the chances of parotid gland tumor development? A systematic review and meta-analysis. J Oral Pathol Med 2017;46:480-3.
  5. Pan SY, de Groh M, Morrison H. A Case-Control Study of Risk Factors for Salivary Gland Cancer in Canada. J Cancer Epidemiol 2017;2017:4909214-.
  6. Lin HH, Limesand KH, Ann DK. Current State of Knowledge on Salivary Gland Cancers. Crit Rev Oncog 2018;23:139-51.
  7. Gonzalez-Pardo V, Suares A, Verstuyf A, De Clercq P, Boland R, de Boland AR. Cell cycle arrest and apoptosis induced by 1alpha,25(OH)2D3 and TX 527 in Kaposi sarcoma is VDR dependent. J Steroid Biochem Mol Biol 2014;144 Pt A:197-200.
  8. Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G. Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. Physiol Rev 2016;96:365-408.
  9. Qin W, Holick MF, Sorensen W, Walker CR, Sauter ER. Vitamin D3 Treatment Influences PGE2 and TGFβ in Normal and Increased Breast Cancer Risk Women. Anticancer Res 2016;36:5347-53.
  10. Xu Y, Shao X, Yao Y, Xu L, Chang L, Jiang Z, et al. Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis. J Cancer Res Clin Oncol 2014;140:1465-77.
  11. Chandler PD, Buring JE, Manson JE, Giovannucci EL, Moorthy M, Zhang S, et al. Circulating vitamin D levels and risk of colorectal cancer in women. Cancer Prev Res (Phila) 2015: canprevres. 0470.2014.
  12. Arem H, Weinstein S, Horst R, Virtamo J, Yu K, Albanes D, et al. Serum 25-hydroxyvitamin D and risk of oropharynx and larynx cancers in Finnish men. Cancer Epidemiol Biomarkers Prev 2011:cebp. 0153. 2011.
  13. Yan L, Gu Y, Luan T, Miao M, Jiang L, Liu Y, et al. Associations between serum vitamin D and the risk of female reproductive tumors: A meta-analysis with trial sequential analysis. Medicine 2018;97.
  14. Stumpf WE, Hayakawa N. Salivary glands epithelial and myoepithelial cells are major vitamin D targets. Eur J Drug Metab Pharmacokinet 2007; 32: 123-9.
  15. Huang Z, Liu Y, Huang Z, Li H, Gan X, Shen Z. 1,25-Dihydroxyvitamin D3 alleviates salivary adenoid cystic carcinoma progression by


suppressing GPX1 expression through the NF-kappaB pathway. Int J Oncol 2016;48:1271-9.

  1. Hohaus S, Tisi MC, Bellesi S, Maiolo E, Alma E, Tartaglia G, et al. Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy. Cancer Med 2018;7:270-81.
  2. Drake MT, Maurer MJ, Link BK, Habermann TM, Ansell SM, Micallef IN, et al. Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. Journal of clinical oncology 2010; 28: 4191.
  3. Orell-Kotikangas H, Schwab U, Osterlund P, Saarilahti K, Makitie O, Makitie AA. High prevalence of vitamin D insufficiency in patients with head and neck cancer at diagnosis. Head Neck 2012; 34: 1450-5.
  4. Calmarza P, Sanz Paris A, Prieto Lopez C, Llorente Barrio M, Boj Carceller D. [Vitamin D levels in patients with recent cancer diagnosis]. Nutr Hosp 2018;35:903-8.
  5. Van Loon K, Owzar K, Jiang C, Kindler HL, Mulcahy MF, Niedzwiecki D, et al. 25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance). J Natl Cancer Inst 2014;106.
  6. Ng K, Sargent DJ, Goldberg RM, Meyerhardt JA, Green EM, Pitot HC, et al. Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. Journal of Clinical Oncology 2011;29:1599.
  7. Tabrizi R, Moosazadeh M, Akbari M, Dabbaghmanesh MH, Mohamadkhani M, Asemi Z, et al. High prevalence of vitamin d deficiency among iranian population: A systematic review and meta-analysis. Iran J Med Sci 2018;43:125.
  8. McCullough ML, Stevens VL, Patel R, Jacobs EJ, Bain EB, Horst RL, et al. Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort. Breast cancer research 2009;11:R64.
  9. Piper MR, Freedman DM, Robien K, Kopp W, Rager H, Horst RL, et al. Vitamin D–binding protein and pancreatic cancer: a nested case-control study–. Am J Clin Nutr 2015;101:1206-15.
  10. Park SM, Li T, Wu S, Li W-Q, Qureshi AA, Cho E. Vitamin D intake and risk of skin cancer in US women and men. PloS one 2016;11:e0160308.
  11. Woloszynska-Read A, Johnson CS, Trump DL. Vitamin D and cancer: clinical aspects. Best Practice & Research Clinical Endocrinology & Metabolism 2011; 25:605-15.
  12. Grimm M, Cetindis M, Biegner T, Lehman M, Munz A, Teriete P, et al. Serum vitamin D levels of patients with oral squamous cell carcinoma (OSCC) and expression of vitamin D receptor in oral precancerous lesions and OSCC. Med Oral Patol Oral Cir Bucal 2015;20:e188.